Team

Founder, President & Chief Executive Officer

Dr. Katamreddy is an accomplished medicinal chemist and biotechnology executive with more than three decades of experience spanning academia, global pharmaceutical research and development, and entrepreneurial drug discovery. He is the author and/or co-author of more than 40 peer-reviewed scientific publications and patents.

He earned his Ph.D. in Organic Chemistry from Pondicherry University and held research appointments at the University of Hyderabad, the University of Barcelona, and Emory University. He began his industry career at GlaxoSmithKline, advancing to Principal Scientist and Research Investigator, and later co-founded Vijaya Pharmaceuticals, LLC.

At SPV Therapeutics, Dr. Katamreddy leads the development of a next-generation CDK inhibitor platform, including SPV374, a differentiated enantiopure CDK4/6/9 inhibitor designed to address RB-independent biology, p53-mutated resistance mechanisms, and safety limitations associated with first-generation CDK4/6 therapies. 

Administration

Vijaya L. Katamreddy, B.Sc., B.Ed., AAS (Clinical Research & Data Management Professional)

Secretary and Treasurer

Vijaya Katamreddy serves as Secretary of SPV Therapeutics, Inc., a role she has held since the company’s formation in 2017. Her responsibilities include overseeing finance administration, corporate records, and internal documentation that support transparency and accountability. Ms. Katamreddy’s role focuses on ensuring continuity, documentation integrity, and organizational readiness as SPV Therapeutics conducts its research activities and evaluates strategic and partnering opportunities.

Advisors

Scientific and strategic advisory board appointments will be announced in due course.